Clinical Trials in Anyang, Henan
58 recruiting
Showing 1–20 of 57 trials
Recruiting
Phase 1Phase 2
Assessment of the Efficacy and Safety of Injectable TQB2934 (Subcutaneous Injection) in Systemic Light Chain Amyloidosis Patients
Systemic Light Chain Amyloidosis
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.70 enrolled27 locationsNCT07266116
Recruiting
Phase 3
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Non-small Cell Lung Cancer (NSCLC)
Amgen750 enrolled380 locationsNCT05920356
Recruiting
Phase 3
Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Posterior Circulation Large Vessel Occlusion Stroke
Ischemic Stroke
Capital Medical University348 enrolled13 locationsNCT07509645
Recruiting
Early Phase 1
SPH5030 Tablets in Subjects With Advanced Her2-positive Solid Tumors
HER2-Positive Advanced Solid Tumors
Shanghai Pharmaceuticals Holding Co., Ltd150 enrolled17 locationsNCT05245058
Recruiting
Phase 1Phase 2
A Clinical Trial on the Efficacy and Safety of TQB6411 for Injection
Advanced Lung Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.465 enrolled37 locationsNCT07367529
Recruiting
Phase 2Phase 3
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Breast Neoplasms
Bristol-Myers Squibb500 enrolled294 locationsNCT06926868
Recruiting
Phase 3
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
Non-small Cell Lung Cancer
Summit Therapeutics1,600 enrolled253 locationsNCT05899608
Recruiting
Phase 3
A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction AdenocarcinomaMetastatic Gastric Adenocarcinoma
BeOne Medicines351 enrolled85 locationsNCT07043400
Recruiting
Phase 3
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
Marginal Zone LymphomaRelapsed/Refractory Follicular Lymphoma
BeiGene780 enrolled277 locationsNCT05100862
Recruiting
Phase 2Phase 3
Pirfenidone Capsules in the Treatment of Radiation-induced Lung Injury With or Without Immune Pneumonia
Radiation Induced Lung InjuryImmune-related Pneumonia
Beijing Continent Pharmaceutical Co, Ltd.298 enrolled36 locationsNCT07388680
Recruiting
Phase 2Phase 3
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Non-small Cell Lung Cancer
Bristol-Myers Squibb596 enrolled186 locationsNCT07100080
Recruiting
Phase 3
RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)
Non-small Cell Lung Cancer
RemeGen Co., Ltd.574 enrolled66 locationsNCT07416474
Recruiting
Phase 2
Phase II Study of RC1416 Injection in COPD
Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Nanjing RegeneCore Biotech Co., Ltd.180 enrolled41 locationsNCT07402551
Recruiting
Phase 1Phase 2
A Phase Ib/II Study of ATG-022 Plus Pembrolizumab With/Without Chemotherapy in Participants With Claudin (CLDN) 18.2-positive, HER2-negative, Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaUnresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Antengene Biologics Limited132 enrolled30 locationsNCT07327229
Recruiting
Phase 1Phase 2
A Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract Cancer
Biliary Tract Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.102 enrolled43 locationsNCT06431490
Recruiting
Phase 3
A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
HER2-positive Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.544 enrolled78 locationsNCT07043725
Recruiting
Not Applicable
Clinical Outcomes of Drug-Coated Balloons in the Treatment of Patients With Coronary De Novo Chronic Total Occlusion Lesions
Coronary Artery Disease (CAD)Chronic Total Occlusions of Coronary Arterieschronic total occlusion (CTO)
The First Affiliated Hospital of Zhengzhou University200 enrolled18 locationsNCT07463664
Recruiting
Phase 1Phase 2
A Phase Ib/Ⅱ Clinical Trial of LBL-024 Combined With Paclitaxel in Patients With Platinum-resistant Ovarian Cancer
Ovarian Cancer
Nanjing Leads Biolabs Co.,Ltd110 enrolled13 locationsNCT07042802
Recruiting
Phase 2
A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)]
Advanced Solid Tumour
Nanjing Leads Biolabs Co.,Ltd110 enrolled7 locationsNCT07331155
Recruiting
Phase 3
A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy
Small Cell Lung Cancer
Akeso560 enrolled53 locationsNCT07010263